Ravulizumab

CAS No. 1803171-55-2

Ravulizumab( —— )

Catalog No. M36750 CAS No. 1803171-55-2

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 375 Get Quote
5MG 588 Get Quote
10MG 943 Get Quote
25MG 1352 Get Quote
50MG 1822 Get Quote
100MG 2412 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Ravulizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation.
  • Description
    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    Complement System
  • Recptor
    Complement System
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1803171-55-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee JW, et, al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530-539. ?
molnova catalog
related products
  • NDT 9513727

    NDT 9513727 is a potent, selective and orally bioavailable C5a receptor inverse agonist with IC50 of 11.6 nM in radioligand binding assay.

  • BR103

    BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22?±?8 ?nM.

  • Complement C5-IN-1

    Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).